Analyst firms · B. Riley Securities · MDGL

B. Riley Securities MDGL price target and rating history

Madrigal Pharmaceuticals Inc. (MDGL) · Health Care

B. Riley Securities rates Madrigal Pharmaceuticals Inc. (MDGL) Buy with a $422 price target, as of its latest action on Feb 28, 2025. It has published 4 rating actions on MDGL since July 2022, including 2 upgrades and 2 downgrades. Across 5 firms with a MDGL price target in the last 12 months, the median target is $704.

Current rating
Buy
Price target
$422
Median target, all firms
$704
Actions on MDGL
4

B. Riley Securities price target on MDGL

$422$249$752023202420252026
B. Riley Securities price target on MDGL, each point a stated target, July 2022 to February 2025.

Every B. Riley Securities rating on MDGL

How other firms rate MDGL

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Goldman SachsBuy$704Sep 24, 2026
CitigroupBuy$725Sep 23, 2026
Wolfe ResearchOutperform$605Aug 4, 2026
Wells FargoOverweight$685Jul 27, 2026
BarclaysOverweight$964Jan 28, 2026

Questions about B. Riley Securities and MDGL

What is B. Riley Securities's price target for MDGL?
B. Riley Securities's latest stated price target for Madrigal Pharmaceuticals Inc. (MDGL) is $422, from its action on Feb 28, 2025.
What is B. Riley Securities's rating on MDGL?
B. Riley Securities rates MDGL Buy, a bullish rating, as of Feb 28, 2025.
When did B. Riley Securities last change its view on MDGL?
On Feb 28, 2025, B. Riley Securities upgrades to Buy from Neutral, price target $236 to $422.
How does B. Riley Securities's MDGL target compare with other analysts?
Across 5 firms with a MDGL price target in the last 12 months, the median target is $704.

More MDGL rating histories

All B. Riley Securities ratingsMDGL news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.